1. Home
  2. ABVC vs RNAZ Comparison

ABVC vs RNAZ Comparison

Compare ABVC & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

SELL

Current Price

$0.91

Market Cap

26.7M

Sector

Health Care

ML Signal

SELL

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

SELL

Current Price

$1.29

Market Cap

27.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ABVC
RNAZ
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.7M
27.9M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
ABVC
RNAZ
Price
$0.91
$1.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 27.1K
18.6K
Earning Date
11-10-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 7.14
N/A
EPS
★ N/A
N/A
Revenue
★ $509,589.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$171.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$1.29
52 Week High
$2.94
$12.60

Technical Indicators

Market Signals
Indicator
ABVC
RNAZ
Relative Strength Index (RSI) 50.16 35.10
Support Level $0.92 N/A
Resistance Level $1.12 $1.93
Average True Range (ATR) 0.07 0.15
MACD -0.00 -0.01
Stochastic Oscillator 51.81 13.49

Price Performance

Historical Comparison
ABVC
RNAZ

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Share on Social Networks: